Evidence map›Paper›PMID 39259813›Full record

ArticleScience translational medicine2024

HIF-2α drives hepatic Kupffer cell death and proinflammatory recruited macrophage activation in nonalcoholic steatohepatitis.

Ishtiaq Jeelani, Jae-Su Moon, Flavia Franco da Cunha, Chanond A Nasamran, Seokhyun Jeon, Xinhang Zhang, Gautam K Bandyopadhyay, Katarzyna Dobaczewska, Zbigniew Mikulski, Mojgan Hosseini and 7 more

Abstract read
In one paragraph

Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Advancing high-altitude medicine: a model for the future.Signal transduction and targeted therapy · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ishtiaq JeelaniDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9903-6326
Jae-Su MoonDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-1724-8614
Flavia Franco da CunhaDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-8209-7421
Chanond A NasamranCenter for Computational Biology & Bioinformatics, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Seokhyun JeonDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-7140-1296
Xinhang ZhangDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0009-0006-2475-7536
Gautam K BandyopadhyayDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-6470-4005
Katarzyna DobaczewskaMicroscopy and Histology Core Facility, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-6377-018X
Zbigniew MikulskiMicroscopy and Histology Core Facility, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-1918-9216
Mojgan HosseiniDepartment of Pathology, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA.
Xiao LiuDepartment of Surgery, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-7608-5819
Tatiana KisselevaDepartment of Surgery, University of California, San Diego, La Jolla, CA 92093, USA.
David A BrennerDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-2573-525X
Seema SinghDivision of Gastroenterology, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0009-0001-3020-0674
Rohit LoombaDivision of Gastroenterology, University of California, San Diego, La Jolla, CA 92093, USA.
Minkyu KimDepartment of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0001-9317-1658
Yun Sok LeeDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-7967-4734

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Yeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8M
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HIDEKAZU TSUKAMOTO · 1999 to 2026
$45.8M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Transcriptional co-regulators and macrophage gene expressionR01DK091183 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2011 to 2025
$9.9M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
HIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7M
Inactivation of Hepatic Stellate Cells During Reversal of Liver FibrosisR01DK099205 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2014 to 2025
$4.8M
The Role of Portal Fibroblasts in Cholestatic Liver FibrosisR01DK101737 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KISSELEVA, TATIANA · 2014 to 2025
$3.8M
NCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA023100NHLBI NIH HHS P01 HL147835NHLBI NIH HHS R01 HL142214NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA028550NIAAA NIH HHS U01 AA029019NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK091183NIDDK NIH HHS R01 DK099205NIDDK NIH HHS R01 DK101737NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01 DK124298NIDDK NIH HHS R01 DK124318NIDDK NIH HHS R44 DK115242NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK130190NIEHS NIH HHS P42 ES010337NINDS NIH HHS P30 NS047101
6 · The paper itself

Abstract

Proinflammatory hepatic macrophage activation plays a key role in the development of nonalcoholic steatohepatitis (NASH). This involves increased embryonic hepatic Kupffer cell (KC) death, facilitating the replacement of KCs with bone marrow-derived recruited hepatic macrophages (RHMs) that highly express proinflammatory genes. Moreover, phago/efferocytic activity of KCs is diminished in NASH, enhancing liver inflammation. However, the molecular mechanisms underlying these changes in KCs are not known. Here, we show that hypoxia-inducible factor 2α (HIF-2α) mediates NASH-associated decreased KC growth and efferocytosis by enhancing lysosomal stress. At the molecular level, HIF-2α stimulated mammalian target of rapamycin (mTOR)- and extracellular signal-regulated kinase-dependent inhibitory transcription factor EB (TFEB) phosphorylation, leading to decreased lysosomal and phagocytic gene expression. With increased metabolic stress and phago/efferocytic burden in NASH, these changes were sufficient to increase lysosomal stress, causing decreased efferocytosis and lysosomal cell death. Of interest, HIF-2α-dependent TFEB regulation only occurred in KCs but not RHMs. Instead, in RHMs, HIF-2α promoted mitochondrial reactive oxygen species production and proinflammatory activation by increasing ANT2 expression and mitochondrial permeability transition. Consequently, myeloid lineage-specific or KC-specific HIF-2α depletion or the inhibition of mTOR-dependent TFEB inhibition using antisense oligonucleotide treatment protected against the development of NASH in mice. Moreover, treatment with an HIF-2α-specific inhibitor reduced inflammatory and fibrogenic gene expression in human liver spheroids cultured under a NASH-like condition. Together, our results suggest that macrophage subtype-specific effects of HIF-2α collectively contribute to the proinflammatory activation of liver macrophages, leading to the development of NASH.

Indexed as

Basic Helix-Loop-Helix ProteinsKupffer CellsLiverMacrophage ActivationNon-alcoholic Fatty Liver DiseaseAnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell DeathEndothelial PAS Domain-Containing Protein 1HumansInflammationLysosomesMacrophagesMiceMice, Inbred C57BLMitochondriaBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Reactive Oxygen SpeciesTcfeb protein, mouseTOR Serine-Threonine Kinases

Identifiers

PMID39259813
PMCPMC11665927

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.